关键词: COVID‐19 XBB.1.5 vaccine Europe SARS‐CoV‐2 hospitalisation vaccine effectiveness

Mesh : Humans Hospitalization / statistics & numerical data COVID-19 / prevention & control epidemiology COVID-19 Vaccines / immunology administration & dosage Aged Europe / epidemiology Female Male Middle Aged Adult Case-Control Studies SARS-CoV-2 / immunology Vaccine Efficacy / statistics & numerical data Vaccination / statistics & numerical data Young Adult Aged, 80 and over Adolescent

来  源:   DOI:10.1111/irv.13360   PDF(Pubmed)

Abstract:
We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.
摘要:
我们进行了一项多中心测试阴性病例对照研究,涵盖2023年10月至2024年1月,在欧洲因严重急性呼吸道感染住院的年龄≥18岁的成年患者中。我们提供了新适应的XBB.1.5COVID-19疫苗对PCR确认的SARS-CoV-2住院的有效性的早期估计。疫苗总有效率为49%,疫苗接种后14-29天的69%和60-105天的40%之间。适应的XBB.1.5COVID-19疫苗在疫苗接种后的前3.5个月内提供了预防COVID-19住院的保护,在疫苗接种后1个月内,老年人(≥65岁)的VE>70%。
公众号